Sight Sciences (SGHT) Set to Release Quarterly Earnings on Wednesday

Sight Sciences (NASDAQ:SGHT) is expected to be issuing its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $23.51 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10. The business had revenue of $23.39 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, analysts expect Sight Sciences to post ($0.48) EPS for the current fiscal year and ($0.37) EPS for the next fiscal year.

Sight Sciences Trading Up 3.3%

Shares of NASDAQ SGHT traded up $0.30 on Wednesday, reaching $9.33. 24,236 shares of the company traded hands, compared to its average volume of 271,263. The company has a 50 day moving average of $8.52 and a 200 day moving average of $5.98. Sight Sciences has a fifty-two week low of $3.38 and a fifty-two week high of $9.71. The stock has a market capitalization of $513.92 million, a PE ratio of -16.66 and a beta of 2.45.

Analyst Ratings Changes

Several equities research analysts recently weighed in on SGHT shares. UBS Group increased their price objective on shares of Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. HC Wainwright initiated coverage on shares of Sight Sciences in a report on Thursday, October 15th. They issued a “buy” rating and a $14.00 price objective for the company. Citigroup boosted their price objective on Sight Sciences from $8.00 to $10.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Wall Street Zen upgraded shares of Sight Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $9.25.

Insider Activity at Sight Sciences

In other Sight Sciences news, EVP Brenton Taylor sold 2,988 shares of the firm’s stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $8.85, for a total transaction of $26,443.80. Following the completion of the transaction, the executive vice president owned 261,990 shares in the company, valued at $2,318,611.50. This trade represents a 1.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO David Badawi sold 7,797 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $70,562.85. Following the completion of the sale, the chief technology officer directly owned 1,975,075 shares in the company, valued at approximately $17,874,428.75. This represents a 0.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,646 shares of company stock worth $429,157 in the last three months. Corporate insiders own 30.40% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc is an ophthalmic medical technology company focused on developing and commercializing products designed to address the underlying causes of certain eye diseases. The company’s portfolio is centered on minimally invasive and non-invasive procedures intended to improve patient outcomes while supporting physicians in the treatment of glaucoma and ocular surface disease.

Its primary products include the OMNI Surgical System, a minimally invasive glaucoma surgery device used to reduce intraocular pressure by improving the eye’s natural fluid outflow pathways, and the TearCare System, a thermal pulsation technology designed to treat meibomian gland dysfunction, a common cause of evaporative dry eye disease.